NOX 100

Drug Profile

NOX 100

Alternative Names: Norathiol; NOX-100

Latest Information Update: 13 Jan 2016

Price : $50

At a glance

  • Originator Medinox
  • Developer Medinox; Orient Europharma
  • Class Free radicals; Nitrogen oxides; Small molecules; Vascular disorder therapies
  • Mechanism of Action Nitric oxide inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Intradialytic hypotension
  • Phase I/II Septic shock
  • Discontinued Acute lung injury; Adult respiratory distress syndrome; Transplant rejection

Most Recent Events

  • 01 Jul 2015 Medinox and Orient Europharma completes a phase II trial in Intradialytic hypotension in Taiwan (IV) (NCT01672008)
  • 08 Jun 2015 Phase-I/II clinical development is ongoing for septic shock, and phase-II development is ongoing for intradialytic hypotension
  • 02 Apr 2014 NOX 100 is still in phase IIa trials for Intradialytic hypotension in Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top